Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B known ✓ | Q02880 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29829553 | 1.00 | TOP2A (0.38) | TOP2ATOP2B | |
| SCHEMBL5496734 | 0.98 | TOP2A (0.35) | TOP2ATOP2B | |
| SCHEMBL5496738 | 0.98 | TOP2A (0.35) | TOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL28347496 | 0.82 | TOP2A (0.42) | TOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL535313 | 0.82 | TOP2A (0.42) | TOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL16262503 | 0.82 | TOP2A (0.42) | TOP2ATOP2B | |
| SCHEMBL28356386 | 0.81 | TOP2A (0.36) | TOP2ATOP2B | |
| SCHEMBL224097 | 0.80 | TOP2A (0.40) | TOP2ATOP2B | |
| SCHEMBL18298166 | 0.78 | TOP2A (0.39) | TOP2ATOP2B | |
| SCHEMBL9787911 | 0.75 | LMNA (0.36) | TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743120-B1 | APPARATUS AND METHOD OF USING IN SITU SOLIDIFYING COMPLEX COACERVATES FOR VASCULAR OCCLUSION | FLUIDX MEDICAL TECH INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3872573-B1 | TONER ADDITIVE FORMULATION WITH CROSS-LINKED ORGANIC POLYMERIC ADDITIVE | XEROX CORP (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12252568-B2 | Silicone copolymer surface additive | XEROX CORPORATION (US) | 2025-03-18 | — | — | US | disclosed |
| US-12220498-B2 | In situ solidifying solutions and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-02-11 | — | — | US | disclosed |
| CN-119343385-A | Free radical polymerizable composition and polymer thereof | 株式会社日本触媒 | 2025-01-21 | — | — | CN | disclosed |
| CN-118652368-A | Water-absorbent resin, preparation method thereof and absorber | 中国天辰工程有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-11896234-B2 | Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion | FLUIDX MEDICAL TECHNOLOGY, LLC (US) | 2024-02-13 | — | — | US | disclosed |
| CN-117222682-A | Cured resin composition and cured product thereof | 日本化药株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-115003711-B | Resin fine particles and method for producing same | 积水化成品工业株式会社 | 2023-11-24 | — | — | CN | disclosed |
| CN-116888159-A | Process for producing modified conjugated diene polymer latex | 日本瑞翁株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20150119353-A1 | ANTIMICROBIAL COMPOSITIONS, THE PREPARATION AND USE THEREOF | KCI LICENSING, INC. | 2015-04-30 | — | — | US | disclosed |
| WO-2015040168-A1 | NOVEL POLYMERS FROM UROCANIC ACID (4-IMIDAZOLACRYLIC ACID) | BASF SE (DE) | 2015-03-26 | — | — | WO | disclosed |
| US-20150038400-A1 | Compositions, the Preparation and Use Thereof | KCI LICENSING, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2817013-A2 | ANTIMICROBIAL COMPOSITIONS, THE PREPARATION AND USE THEREOF | KCI Licensing Inc. (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2575906-B1 | REINFORCED ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF | UNIV UTAH RES FOUND (US) | 2014-12-10 | — | — | EP | disclosed |
| WO-2014123665-A1 | POLYMERS, PREPARATION AND USE THEREOF | KCI LICENSING, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20130273145-A1 | COMPOSITIONS, THE PREPARATION AND USE THEREOF | KCI LICENSING, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2013126550-A2 | NEW COMPOSITIONS, THE PREPARATION AND USE THEREOF | KCI LICENSING, INC. (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20110287067-A1 | REINFORCED ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2011-11-24 | — | — | US | disclosed |
| US-20090048381-A1 | PROCESS FOR MAKING POLYOLEFIN CLAY NANOCOMPOSITES | NOVA CHEMICAL INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119353-A1 | ANTIMICROBIAL COMPOSITIONS, THE PREPARATION AND USE THEREOF | CUTA, CHCHD6, IMMT | TOP2A 937/4885TOP2B 2267/4885 |
| US-20110287067-A1 | REINFORCED ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF | COL14A1, COL2A1, PUF60 | TOP2A 2643/4885TOP2B 2821/4885 |
| US-12220498-B2 | In situ solidifying solutions and methods of making and using thereof | VCL, ILK, SELE | TOP2A 4245/4885TOP2B 4738/4885 |
| US-20130273145-A1 | COMPOSITIONS, THE PREPARATION AND USE THEREOF | CD14, EPCAM, BOD1L1 | TOP2A 1980/4885TOP2B 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.